Stoke Therapeutics Inc (STOK) - Net Assets
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has net assets worth $345.55 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($393.97 Million) and total liabilities ($48.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check STOK PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $345.55 Million |
| % of Total Assets | 87.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | 61.84% |
| 10-Year Change | N/A |
| Growth Volatility | 45.53 |
Stoke Therapeutics Inc - Net Assets Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see STOK market cap.
Annual Net Assets for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual net assets of Stoke Therapeutics Inc from 2017 to 2025. Also explore Stoke Therapeutics Inc (STOK) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $352.46 Million | +53.90% |
| 2024-12-31 | $229.02 Million | +43.53% |
| 2023-12-31 | $159.56 Million | -13.68% |
| 2022-12-31 | $184.85 Million | -15.12% |
| 2021-12-31 | $217.78 Million | -23.87% |
| 2020-12-31 | $286.08 Million | +27.47% |
| 2019-12-31 | $224.43 Million | +113.60% |
| 2018-12-31 | $105.07 Million | +8232.20% |
| 2017-12-31 | $-1.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Stoke Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48452600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $543.00K | 0.15% |
| Other Components | $849.62 Million | 241.06% |
| Total Equity | $352.46 Million | 100.00% |
Stoke Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Stoke Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ola Electric Mobility Ltd
NSE:OLAELEC
|
$1.82 Billion |
|
Stanmore Resources Ltd
AU:SMR
|
$1.82 Billion |
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
$1.82 Billion |
|
Australian United Investment Company Ltd
AU:AUI
|
$1.82 Billion |
|
Devyani International Limited
NSE:DEVYANI
|
$1.82 Billion |
|
Rendong Holdings Co Ltd
SHE:002647
|
$1.82 Billion |
|
City Union Bank Limited
NSE:CUB
|
$1.81 Billion |
|
Dalian Zeus Entertainment
SHE:002354
|
$1.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stoke Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 229,021,000 to 352,457,000, a change of 123,436,000 (53.9%).
- Net loss of 6,885,000 reduced equity.
- New share issuances of 87,784,000 increased equity.
- Other comprehensive income increased equity by 694,000.
- Other factors increased equity by 41,843,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.88 Million | -1.95% |
| Share Issuances | $87.78 Million | +24.91% |
| Other Comprehensive Income | $694.00K | +0.2% |
| Other Changes | $41.84 Million | +11.87% |
| Total Change | $- | 53.90% |
Book Value vs Market Value Analysis
This analysis compares Stoke Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.05 | $28.15 | x |
| 2018-12-31 | $4.47 | $28.15 | x |
| 2019-12-31 | $12.49 | $28.15 | x |
| 2020-12-31 | $8.54 | $28.15 | x |
| 2021-12-31 | $5.93 | $28.15 | x |
| 2022-12-31 | $4.75 | $28.15 | x |
| 2023-12-31 | $3.63 | $28.15 | x |
| 2024-12-31 | $4.24 | $28.15 | x |
| 2025-12-31 | $5.95 | $28.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stoke Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.73%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.19x
- Recent ROE (-1.95%) is above the historical average (-26.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.43 Million |
| 2018 | -11.92% | 0.00% | 0.00x | 1.02x | $-23.03 Million |
| 2019 | -12.71% | 0.00% | 0.00x | 1.02x | $-50.97 Million |
| 2020 | -17.69% | 0.00% | 0.00x | 1.04x | $-79.22 Million |
| 2021 | -38.90% | -2823.70% | 0.01x | 1.10x | $-106.49 Million |
| 2022 | -50.37% | -750.58% | 0.05x | 1.39x | $-111.59 Million |
| 2023 | -65.62% | -1192.47% | 0.04x | 1.43x | $-120.66 Million |
| 2024 | -38.85% | -243.42% | 0.13x | 1.19x | $-111.88 Million |
| 2025 | -1.95% | -3.73% | 0.44x | 1.19x | $-42.13 Million |
Industry Comparison
This section compares Stoke Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stoke Therapeutics Inc (STOK) | $345.55 Million | 0.00% | 0.14x | $1.82 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more